-
00:00
1.
index 1
-
27:01
2.
HBV
-
30:05
3.
Slide 2
-
32:06
4.
Slide 3
-
33:10
5.
Slide 2
-
33:14
6.
Slide 3
-
33:19
7.
Slide 2
-
33:21
8.
Slide 3
-
35:10
9.
Chronic carrier- HBs Ag+ ≧ 6m
-
36:27
10.
Infancy’s fulminant hepatitis in Taiwan
-
37:14
11.
HBV vaccine
-
41:00
12.
保護力: 母 HBeAg + → 子 ① HBIG + 1st HBV vaccine => 85-95% 保護力 ② 1st HBV vaccine => 70-80% 保護力 母 HBeAg -, anti-HBe +carrier rate: 10%vaccine+: carrier rate: 4%; be wary of 6-9% become fulminant hepatitisVaccine+, HBIG+
-
42:11
13.
Slide 8
-
42:49
14.
Slide 9
-
43:30
15.
Pretreatment evaluation
-
45:50
16.
Testing for coinfection1. HCV – Test for HCV in all children with HBV Coinfection with HCV increases the risk for progressive liver disease informs decisions about antiviral treatment, because of the risk of HBV reactivation during treatment for HCV Hepa
-
46:40
17.
Antiviral treatment of chronic HBV in children
-
47:55
18.
Slide 13
-
51:14
19.
Antiviral treatment of chronic HBV in children
-
52:21
20.
** after HBV comment.pptx